Arbutus Biopharma Corp Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Arbutus Biopharma Corp (ABUS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $6.91 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2019-03-07
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2016-12-31 was $5.02M.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2016-09-30 was -$120.70K.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2016-06-30 was -$39.00K.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2016-03-31 was $200.00K.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2018 was $6.91M, a 22.21% increase from fiscal 2017.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2017 was $5.66M, a 11.84% increase from fiscal 2016.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2016 was $5.06M, a 194.41% increase from fiscal 2015.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2015 was $1.72M, a 31.42% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | $6.91M 10-K · filed 2019-03-07 | ||||
| 2017-12-31 | $5.66M 10-K · filed 2019-03-07 | ||||
| 2016-12-31 | $5.02M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $4.90M derived: sum of 2 quarters · filed 2018-03-16 | $4.86M derived: sum of 3 quarters · filed 2018-03-16 | $5.06M 10-K · filed 2018-03-16 | |
| 2016-09-30 | -$120.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$159.70K derived: sum of 2 quarters · filed 2016-11-03 | $40.30K 10-Q · filed 2016-11-03 | ||
| 2016-06-30 | -$39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $161.00K 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $200.00K 10-Q · filed 2016-05-04 | ||||
| 2015-12-31 | $1.72M 10-K · filed 2018-03-16 | ||||
| 2014-12-31 | $2.50M 10-K · filed 2017-03-22 | ||||
| 2013-12-31 | $955.00K 10-K · filed 2016-03-09 | $954.53K 6-K · filed 2014-03-06 | |||
| 2012-12-31 | $1.07M 10-K · filed 2015-03-13 | $1.07M 6-K · filed 2014-03-06 | |||
| 2011-12-31 | $355.66K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |